{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:15:43Z","timestamp":1783574143371,"version":"3.55.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Diabetic kidney disease (DKD) remains a leading cause of end-stage kidney disease despite advances with renin\u2013angiotensin system blockade, sodium\u2013glucose cotransporter 2 inhibitors, finerenone, and glucagon-like peptide-1 receptor agonists. Therapeutic monoclonal antibodies may offer a targeted strategy to modulate inflammatory, fibrotic, metabolic, and vascular pathways involved in DKD. This review summarizes the mechanistic rationale, clinical evidence, translational barriers, and future prospects of antibody-based therapies for DKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a narrative literature review using PubMed, the Cochrane Library, and ClinicalTrials.gov from database inception to March 31, 2026. We prioritized peer-reviewed preclinical studies, clinical trials, and high-quality reviews addressing mAb-based strategies targeting DKD-related pathways, including TGF-\u03b21, VEGF-B, CTGF, suPAR, integrin \u03b1v\u03b28, signal regulatory protein \u03b1, and PCSK9.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Phase II studies of anti-TGF-\u03b21 and anti-VEGF-B antibodies failed to show meaningful renal benefit, highlighting challenges such as pathway redundancy, delayed intervention, insufficient intrarenal target engagement, and off-kidney toxicity. Anti-CTGF therapy showed an early signal of albuminuria, whereas anti-suPAR remains under clinical evaluation. Emerging preclinical targets, including integrin \u03b1v\u03b28 and signal regulatory protein \u03b1, may provide more kidney-focused modulation of fibrotic and inflammatory pathways. PCSK9 monoclonal antibodies, particularly evolocumab and alirocumab, appear promising because they may confer renal benefit through lipid lowering and kidney-intrinsic effects on lipotoxicity, oxidative stress, AMPK signaling, and profibrotic pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Monoclonal antibodies represent a biologically compelling but clinically underdeveloped strategy for DKD. Future progress will require earlier biomarker-informed patient selection, confirmation of intrarenal target engagement, appropriate renal endpoints, and rational combination with established kidney-protective therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1868198","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:21:46Z","timestamp":1783570906000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic monoclonal antibodies for diabetic kidney disease: a narrative review from basic mechanisms to clinical evidence"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiu Hong","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Nephrology, Huadong Hospital, Fudan University","place":["Shanghai, China"]},{"name":"Shanghai Key Laboratory of Clinical Geriatric Medicine, Huadong Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Huadong Hospital, Fudan University","place":["Shanghai, China"]},{"name":"Shanghai Key Laboratory of Clinical Geriatric Medicine, Huadong Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen Sheng","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Huadong Hospital, Fudan University","place":["Shanghai, China"]},{"name":"Shanghai Key Laboratory of Clinical Geriatric Medicine, Huadong Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui Min","family":"Jin","sequence":"additional","affiliation":[{"name":"Shanghai Dong Ji Fresenius Hemodialysis Center","place":["Shanghai, China"]},{"name":"Division of Nephrology, Shanghai Pudong Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi Bin","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Huadong Hospital, Fudan University","place":["Shanghai, China"]},{"name":"Shanghai Key Laboratory of Clinical Geriatric Medicine, Huadong Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-024-00827-z","article-title":"Combination therapy for kidney disease in people with diabetes mellitus","volume":"20","author":"van Raalte","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000001053","article-title":"Current landscape and emerging therapeutic targets in diabetic kidney disease","author":"Hu","year":"2026","journal-title":"Clin J Am Soc Nephrol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2174\/0115701638387416251203104329","article-title":"Progress in monoclonal antibodies: from lab innovations to life-saving therapies","author":"Masne","year":"2026","journal-title":"Curr Drug Discov Technol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2174\/1871520620666200703191653","article-title":"Therapeutic monoclonal antibodies in clinical practice against cancer","volume":"20","author":"Kaur","year":"2020","journal-title":"Anti-Cancer Agents Med Chem"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxaf046","article-title":"Anti-human TLR7 antibody for therapeutic intervention in systemic lupus erythematosus","volume":"38","author":"Fukui","year":"2026","journal-title":"Int Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01207-9","article-title":"Fifty years of monoclonals: the past, present and future of antibody therapeutics","volume":"25","author":"Chan","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2026.2614669","article-title":"Antibodies to watch in 2026","volume":"18","author":"Crescioli","year":"2026","journal-title":"MAbs"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocpiqo.2023.04.009","article-title":"Contemporary monoclonal antibody utilization in glomerular diseases","volume":"7","author":"Mansour","year":"2023","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.112737","article-title":"Macrophages in focus: key drivers and therapeutic opportunities in diabetic kidney disease","volume":"21","author":"Zhao","year":"2025","journal-title":"Int J Biol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2026.171467","article-title":"Thymosin beta 4: An emerging therapeutic candidate for kidney diseases","volume":"195","author":"Di","year":"2026","journal-title":"Peptides"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13010050","article-title":"Exploring the molecular modalities in the pathogenesis of diabetic kidney disease with a focus on the potential therapeutic implications","volume":"13","author":"Gaydarski","year":"2024","journal-title":"Biomedicines"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2022.2133698","article-title":"Renal fibrosis as a hallmark of diabetic kidney disease: potential role of targeting transforming growth factor-beta (TGF-\u03b2) and related molecules","volume":"26","author":"Tang","year":"2022","journal-title":"Expert Opin Ther Targets"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.579603","article-title":"Thrombotic microangiopathy and acute kidney injury induced after intravitreal injection of vascular endothelial growth factor inhibitors: VEGF blockade-related TMA after intravitreal use","volume":"7","author":"Hanna","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12081723","article-title":"Unraveling the complex molecular interplay and vascular adaptive changes in hypertension-induced kidney disease","volume":"12","author":"Gaydarski","year":"2024","journal-title":"Biomedicines"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06191-8","article-title":"The role of PCSK9 in glomerular lipid accumulation and renal injury in diabetic kidney disease","volume":"67","author":"Wu","year":"2024","journal-title":"Diabetologia"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2010.10.038","article-title":"TGF-\u03b2 sequestration by mesangial cell integrin \u03b1v\u03b28: a novel mechanism of glomerular endothelial cell regulation","volume":"178","author":"Pozzi","year":"2011","journal-title":"Am J Pathol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.183392","article-title":"Myokine SIRP\u03b1 exacerbates kidney disease in diabetes","volume":"11","author":"Wu","year":"2026","journal-title":"JCI Insight"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000001006","article-title":"Targeting \u03b1v\u03b28 integrin with monoclonal antibody MEDI8367 prevents fibrosis in preclinical models of CKD","author":"Marin","year":"2025","journal-title":"Kidney360"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.20257hfnfcky","article-title":"SIRP\u03b1 neutralization reverses kidney lipid metabolism defects, improving kidney function despite hyperglycemia in type 1 diabetes: SA-PO0305","volume":"36","author":"Wu","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2022.146729","article-title":"Modulation of diabetic kidney disease markers by an antagonist of p75NTR in streptozotocin-treated mice","volume":"838","author":"Luu","year":"2022","journal-title":"Gene"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43847-2","article-title":"Anti-VEGFR2 F(ab')2 drug conjugate promotes renal accumulation and glomerular repair in diabetic nephropathy","volume":"14","author":"Liu","year":"2023","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2015111230","article-title":"Anti-TGF-\u03b21 antibody therapy in patients with diabetic nephropathy","volume":"28","author":"Voelker","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000000000438","article-title":"Vascular endothelial growth factor-B blockade with CSL346 in diabetic kidney disease: a phase 2A randomized controlled trial","volume":"35","author":"Cooper","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.09321209","article-title":"Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria","volume":"5","author":"Adler","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B25","unstructured":"Walden Biosciences fully enrolls first cohort in phase 2 basket study of WAL0921 in chronic kidney diseases"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.20256pybbkcw","article-title":"Inhibition of PCSK9 attenuates renal lipotoxicity by activating AMPK signaling in diabetic kidney disease: FR-PO0325","volume":"36","author":"Hong","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2174\/0115701611392964250918094721","article-title":"PCSK9: its role in lipid metabolism and as a novel target for the treatment of metabolic kidney disease","author":"Li","year":"2025","journal-title":"Curr Vasc Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1709009","article-title":"Effectiveness of PCSK9 inhibitors versus statins in type 2 diabetes and dyslipidemia: a propensity-matched study","volume":"16","author":"Wu","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.03.513","article-title":"Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial","volume":"73","author":"Charytan","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa498","article-title":"Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial","volume":"41","author":"Tu\u00f1\u00f3n","year":"2020","journal-title":"Eur Heart J"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.23876\/j.krcp.22.237","article-title":"Genetic variations in HMGCR and PCSK9 and kidney function: a Mendelian randomization study","volume":"42","author":"Park","year":"2023","journal-title":"Kidney Res Clin Pract"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S011","article-title":"Chronic kidney disease and risk management: standards of care in diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"B33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1161\/hypertensionaha.116.07618","article-title":"Mechanisms of hypertension and renal injury during vascular endothelial growth factor signaling inhibition","volume":"68","author":"van den Meiracker","year":"2016","journal-title":"Hypertension"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2016.94","article-title":"Inflammatory cues enhance TGF\u03b2 activation by distinct subsets of human intestinal dendritic cells via integrin \u03b1v\u03b28","volume":"10","author":"Fenton","year":"2017","journal-title":"Mucosal Immunol"},{"key":"B35","article-title":"Amgen takes action with the U.S. government to lower the cost of medicines for American patients","year":"2025"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxad108","article-title":"Interleukin-11 and its eminent role in tissue fibrosis: a possible therapeutic target","volume":"214","author":"O'Reilly","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.202507c4d0yj","article-title":"Role for IL-11 signalling in diabetic nephropathy: SA-PO0323","volume":"36","author":"Widjaja","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2014.184","article-title":"Targeting CTGF, EGF and PDGF pathways to prevent progression of kidney disease","volume":"10","author":"Kok","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/fjc.0000000000001760","article-title":"Time to combinatorial regimens: SGLT2i and PCSK9i in high-risk cardio-oncology patients","volume":"86","author":"Quagliariello","year":"2025","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.03.042","article-title":"Reading the tree leaves-how to enrich clinical trials of diabetic kidney disease","volume":"92","author":"Looker","year":"2017","journal-title":"Kidney Int"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109116","article-title":"Serum soluble urokinase plasminogen activator receptor as a potential biomarker of renal impairment severity in diabetic nephropathy","volume":"182","author":"Lupu\u0219oru","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf022","article-title":"COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR endpoint (CONFIDENCE) trial: baseline clinical characteristics","volume":"40","author":"Agarwal","year":"2025","journal-title":"Nephrol Dial Transplant"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1868198\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:21:48Z","timestamp":1783570908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1868198\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":43,"alternative-id":["10.3389\/fendo.2026.1868198"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1868198","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"article-number":"1868198"}}